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Abstract
Left ventricular hypertrophy leads to heart failure and represents a high risk leading to premature death. Cyclic nucleotides
(cAMP and cGMP) play a major role in heart contractility and cyclic nucleotide phosphodiesterases (PDEs) are involved in
different stages of advanced cardiac diseases. We have investigated their contributions in the very initial stages of left
ventricular hypertrophy development. Wistar male rats were treated over two weeks by chronic infusion of angiotensin II
using osmotic mini-pumps. Left cardiac ventricles were used as total homogenates for analysis. PDE1 to PDE5 specific
activities and protein and mRNA expressions were explored. Rats developed arterial hypertension associated with a slight
cardiac hypertrophy (+24%). cAMP-PDE4 activity was specifically increased while cGMP-PDE activities were broadly
increased (+130% for PDE1; +76% for PDE2; +113% for PDE5) and associated with increased expressions for PDE1A, PDE1C
and PDE5A. The cGMP-PDE1 activation by Ca
2+/CaM was reduced. BNP expression was increased by 3.5-fold, while NOX2
expression was reduced by 66% and AMP kinase activation was increased by 64%. In early cardiac hypertrophy induced by
angiotensin II, all specific PDE activities in left cardiac ventricles were increased, favoring an increase in cGMP hydrolysis by
PDE1, PDE2 and PDE5. Increased cAMP hydrolysis was related to PDE4. We observed the establishment of two
cardioprotective mechanisms and we suggest that these mechanisms could lead to increase intracellular cGMP: i) increased
expression of BNP could increase ‘‘particulate’’ cGMP pool; ii) increased activation of AMPK, subsequent to increase in PDE4
activity and 59AMP generation, could elevate ‘‘soluble’’ cGMP pool by enhancing NO bioavailability through NOX2 down-
regulation. More studies are needed to support these assumptions. Nevertheless, our results suggest a potential link
between PDE4 and AMPK/NOX2 and they point out that cGMP-PDEs, especially PDE1 and PDE2, may be interesting
therapeutic targets in preventing cardiac hypertrophy.
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Introduction
Left ventricular hypertrophy is a major risk factor for premature
death [1]. There is a correlation between plasmatic angiotensin II,
hypertension, development of cardiac hypertrophy [2] and
remodeling leading to heart failure [3]. Molecular mechanisms
altered by angiotensin II have been mainly studied in vessels (for
review see [4]); only a few studies have been performed in heart
[5]. Cyclic nucleotides play a major role in the activation of
different intracellular signaling pathways. In the heart, cyclic
nucleotide phosphodiesterases (PDEs), by hydrolyzing cAMP and/
or cGMP, regulate contractility in response to different stimuli
such as b-adrenergic receptors [6] and natriuretic peptide
receptors [7] and participate to cardiac remodeling [8].
PDEsuperfamilyisconstitutedofelevenfamilies,PDE1toPDE11,
but onlythe five former have been wellstudied [9]. PDE1isactivated
by calmodulin (CaM) in presence of Ca
2+ (PDE1-Ca
2+/CaM
complex). PDE1A and PDE1B hydrolyze mainly cGMP, while
PDE1C hydrolyzes equally cAMP and cGMP. The activations of
PDE1A and PDE1C by Ca/CaM are decreased by PKA
phosphorylation. PDE2 hydrolyzes cGMP and cAMP, and its cAMP
hydrolysis is allosterically activated by cGMP [10]. PDE3 hydrolyzes
both cAMP and cGMP. cGMP has a greater affinity for PDE3 while
being hydrolyzed 10 times slower than cAMP, which makes it acts as
a PDE3 inhibitor. PDE4 hydrolyzes specifically cAMP and could be
activated subsequently through PKA-dependent phosphorylation
while PDE5 hydrolyzes specifically cGMP and could be activated by
cGMP and PKG-dependent phosphorylation [11].
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distribution of PDEs in various forms of cardiac hypertrophy
[12,13] and heart failure [14,15]. Indeed, a decrease in cAMP-
PDE activity, especially PDE3A activity, was observed in
a
2+dvanced cardiac hypertrophy induced by ligation of the aorta
in mice as well as in human failing hearts [16]. In dog, heart
failure was associated with a decrease in membrane expression of
PDE3, without change in cytosolic PDE3 activity [17]. Further-
more, inactivation of the PDE4D gene in mouse was associated
with progressive heart failure and arrhythmias, despite a normal
overall cAMP level [14]. These results are consistent with the
observation that, in spontaneously hypertensive rats subjected to a
chronic b-adrenergic stimulation in vivo, pentoxyfilline (a non-
selective PDE inhibitor) promotes the transition from left
ventricular hypertrophy to left ventricular dilatation [18]. In
cardiomyocytes, cGMP has opposite effects depending on its
compartmentation. The elevation of cGMP due to the stimulation
of particulate guanylyl cyclase (GC) by natriuretic peptides cause
positive inotropic and chronotropic effects [19], mediated by
cGMP/cAMP cross-talk [10]. In contrast, a permeable cGMP
analogue [6] or the stimulation of GC by NO donors through
activation of PKG causes a negative inotropic effect via the
myofilaments [20]. It was interestingly shown that PDE5A was
upregulated in different models of cardiac disease [15,21] and that
early correction of PDE5 alterations could restore heart function
and prevent cardiac hypertrophy [22,23].
Therefore, PDEs in the heart could be valuable therapeutic
targets for the treatment and prevention of cardiac dysfunction.
Since no studies were done investigating simultaneously the
various cAMP- and cGMP-PDE isoform contributions in cardiac
pathology, we aimed to explore the variations of PDE1 to PDE5 in
left cardiac ventricle on a rat model of cardiac hypertrophy
induced by angiotensin II, and especially in the initial stages of
cardiac hypertrophy development.
Materials and Methods
In vivo Treatment of Rats
The study conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institute of Health (NIH
Publication No. 85-23, revised 1996) and has been approved by
the local ethics committee of animal experimentation (CRE-
MEAS). Experimental protocol and physiological measurements
were conducted as previously described [24]. Male Wistar rats (10-
week old) were anesthetized with sodium pentobarbital (50 mg/kg,
i.p.; Centravet). A 1-cm incision was made in the mid-scapular
region and an osmotic mini-pump (Alzet 2004, Charles River
Laboratories) was implanted. Pumps contained angiotensin II
(Sigma-Aldrich, St. Louis, MO, USA), which was dissolved in
saline solution, and the infusion rate was 0.1 mg.kg
21.d
21 (ANGII
0.1) or 0.4 mg.kg
21.d
21 (ANGII 0.4) for 14 days. Sham-operated
rats underwent an identical surgical procedure without pump
implantation. Systolic blood pressure and heart rate were
measured using a tail-cuff plethysmograph connected to a
computerized system (LE 5002, BIOSEB) in conscious rats before
the infusion (D0) and at the end of treatment (D14). Body weight
was also recorded at D0 and D14. Rats were then sacrificed, hearts
were weighted and left cardiac ventricles (LCV) were quickly
frozen in liquid nitrogen and stored at 280uC.
Preparation of Protein Extracts from Left Cardiac
Ventricles
Frozen left ventricles were powdered in liquid nitrogen with a
freezermill (Freezer/Mill 6750 from SPEX CERTIPREP INC).
Grinding protocol included 5 cycles (1 min freezing, 2 min
grinding with 1 min freezing between two grindings). Powders
were suspended (100 mg of tissue/ml) in a protease inhibitor
buffer (20 mM Tris, 2 mM Mg
2 + acetate, 5 mM EGTA, pH 7.5,
1 mM dithiothreitol, 10 mg/ml aprotinin, 10 mg/ml leupeptin,
10 mg/ml soybean trypsin inhibitor, 0.33 mM Pefabloc). Homog-
enates were then mixed and treated by ultrasounds for 10 seconds.
Total homogenates obtained were aliquoted and stored at 280uC
until use. Protein levels were assessed by the Lowry method [25]
using bovine serum albumin (BSA) as standard. DNA levels were
determined by fluorometric measurement as previously described
[26] using a DNA standard provided by Sigma.
Western Blot Analysis
Proteins (30 mg) from left cardiac ventricle homogenates were
subjected to Western blot as described previously [27]. Immuno-
detection was carried out with: anti-PDE1A (PD1A-101AP; 1/
2,500), anti-PDE1B (PD1B-201AP; 1/2,500), anti-PDE1C
(PD1C-301AP; 1/2,500), anti-PDE2A (PD2A-101AP; 1/1,000),
anti-PDE4C (PD4-301AP; 1/2,500), anti-PDE4D (PD4-401AP;
1/2,500), anti-PDE5A (PD5A-101AP; 1/2,500) and anti-phospho-
specific PDE5A (PPD5-140AP; 1/1,000; labels PDE5A proteins
when phosphorylated at Ser92 by protein kinase G (PKG)) from
FabGennix Inc. (Frisco, TX, USA); anti-PDE4A (AC55;1/2,000)
and anti-PDE4B (K118; 1/2,000) from Dr M. Conti [28]; anti-
phospho-AMPKa (Thr172) subunit (2531; 1/1,000) from Cell
Signaling Technology, Inc.; anti-p47-phox (sc-14015; 1/,1000)
from Santa Cruz Biotechnology, Inc.; anti-NOS3 (610297; 1/
2,000) from BD Transduction Laboratories; anti-GAPDH (1/
60,000; Chemicon). Immobilized antigens were detected by
chemiluminescence using horse radish peroxidase-conjugates as
secondary antibodies (1/60,000; Promega), an ECL kit (GE
Healthcare) and autoradiography films. Autoradiography signals
were captured on a GeneGenius Bio Imaging System (Syngene)
using the GeneSnap software and analysed using the GeneTool
software. PDE signal values were normalized with GAPDH signal
values.
PDE Assay
PDE activity was determined with a radioenzymatic assay as
described previously [29]. Total cAMP-PDE activity was assessed
at 1 mM cAMP and the contribution of PDE isozymes was
determined by using selective inhibitors: 1 mM cilostamide for
PDE3 (Ki=45 nM [30]) and 10 mM rolipram for PDE4
(Ki=0.8 mM [30]), the residual cAMP-PDE activity representing
essentially PDE2 [29]. Total cGMP-PDE activity was assessed at
1 mM cGMP and the contribution of PDE isozymes was
determined by using the selective inhibitors: 10 mM nimodipine
for PDE1 (Ki=1.4 mM [30]), 20 mM EHNA for PDE2
(IC50=0.8–2 mM [31]) and 0.1 mM DMPPO for PDE5
(Ki=3 nM [32]). The residual cGMP-PDE activity represented
essentially PDE3, which is able to hydrolyze both cAMP and
cGMP, but with a higher affinity and a 10-fold lower Vmax for
cGMP [29]. As EHNA is effective only on cGMP-stimulated
PDE2 and not on basal PDE2 [33], it was not usable to determine
cAMP-PDE2 activity. Specific activities were expressed as
pmol.min
21.mg
21 protein and for some experiments also as
pmol.min
21.mg
21 DNA.
Quantitative real-time RT-PCR
Total RNA was isolated from left cardiac ventricle using the
RNeasyH kit (Qiagen), including an RNase-free DNase treatment
to prevent co-amplification of genomic DNA. The concentration
Early Cardiac Hypertrophy PDEs
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260 nm. The integrity of purified RNA was checked by agarose
gel electrophoresis in denaturing condition. The reverse transcrip-
tion was performed using iScriptH cDNA synthesis kit from Bio-
Rad. The 18S rRNA house-keeping gene was used for
normalization. Specific primers for PDEs and 18S rRNA were
designed with Primer3 (v. 0.4.0) software using mRNA sequences
retrieved from NCBI nucleotide database and are presented in
Table 1. The transcript levels of PDEs and 18S rRNA were
quantified by real-time PCR performed in the MyiQH single-color
detector system (Bio-Rad Laboratories, Inc.) using the iQ SYBRH
Green Supermix (product no. 170-8884) containing the hot-start
iTaq DNA polymerase. The amplification conditions were: 95uC
for 5 min, 40 cycles at 94uC for 10 sec, 60uC for 10 sec and 72uC
for 15 sec. All amplification efficiencies were 1.060.1. Specificity
of amplification products was assessed by melting curve analysis
and their size was checked by agarose gel electrophoresis. Samples
were processed in triplicate according to the manufacturer’s
guidelines. Relative gene expression was calculated using the
comparative threshold (Ct) method (2
2DDCt) [34].
Immunohistochemistry
Frozen left cardiac ventricles embedded in Tissue-TekH O.C.T
(Sakura Finetek) were cryosectioned (4 mm) and fixed with 4%
paraformaldehyde. Fixed sections were incubated with antibodies
directed against PDE5A (1/100; FabGennix Inc.). The correspond-
ing IgG coupled to Alexa 488 (Invitrogen, Molecular Probes) was
used assecondaryantibody. Imageswereobtained with a LeicaDM
400 inverted epifluorescence microscope (x63 objective).
Statistical Analysis
All data are expressed as mean 6 S.E.M. Statistical analyses
were performed with Student’s t test for unpaired data excepted
for PDE4 enzymatic activities measured with H89 (paired data),
using GraphPad Prism software (San Diego, USA). For Real-Time
PCR, statistical analyses were performed with Student’s t test for
unpaired data as described previously [35]. A value of P,0.05 was
considered as significant.
Results
Effect of angiotensin II treatment on cardiovascular
parameters
Before the implantation of mini-pumps, rats presented similar
systolic blood pressures (12967 mmHg for control rats,
12563 mmHg for 0.1 mg.kg
21.d
21 and 12863 mmHg for
0.4 mg.kg
21.d
21 angiotensin II treated rats). After two week-
treatment, systolic blood pressure was significantly increased (+36%,
P,0.001) only in rats treated with 0.4 mg ANGII (17465m mH g )
compared to control rats (12865m mH g )( Fig. 1A). Heart rate did
not change significantly among the three groups (Fig. 1B). The heart/
body weight ratio was calculated as an indicator for estimating cardiac
hypertrophy. The development of a slight cardiac hypertrophy (+24%,
P=0.02, Fig. 1C) was observed only in rats treated with 0.4 mg
ANGII. This dose was kept for the forthcoming analysis.
PDE isozyme distribution in left cardiac ventricle
In left cardiac ventricle of control rats, PDE4 represented 64%
of total cAMP-PDE activity whereas PDE1, PDE2 and PDE3
contributed respectively for 7%, 9% and 20% (Fig. 2A). PDE2
represented 62% of total cGMP-PDE activity, whereas PDE1,
PDE3 and PDE5 contributed, respectively for 15%, 7% and 16%
for total cGMP-PDE activity (Fig. 2B). This pattern is in
accordance with the PDE mRNA distribution in control left
cardiac ventricle, where PDE2A, PDE4A, PDE4B and PDE4D
are the major PDE transcripts, followed by PDE3A, PDE3B,
PDE5A and PDE1A at almost the same level, and finally PDE4C
and PDE1C are the least expressed (Fig. 3A).
Effect of angiotensin II treatment on PDE activities
As seen in Figure 1, rats treated with angiotensin II at
0.4 mg.kg
21.d
21 for two weeks showed arterial hypertension
associated with cardiac hypertrophy, without developing tachy-
cardia. Although this treatment did not significantly change total
cAMP-PDE activity, it induced a specific 22%-increase in PDE4
activity (P,0.001) (Fig. 2A). On the other side, cGMP-PDE
activities were broadly increased, for PDE1 (+130%, P=0.02),
PDE2 (+76%, P,0.001) and PDE5 (+113%, P=0.002) (Fig. 2B).
Moreover, the total cAMP-PDE/cGMP-PDE activity ratio was
decreased by 31% in hypertrophic left cardiac ventricles,
indicating a shift to a greater cGMP hydrolysis (Fig. 2C).
Because cardiac hypertrophy induces alterations in cellular
protein content and could thus introduce a bias in the
measurement of PDE activity expressed as pmol.min
21.mg
21 of
protein, PDE activity was also expressed as pmol.min
21.mg
21 of
DNA. We observed similar effects: cAMP-PDE4 activity was
increased (+13%), as were cGMP-PDE1 (+105%), cGMP-PDE2
(+60%) and cGMP-PDE5 (+61%) (not illustrated).
Exploration of increased cAMP hydrolysis activity
Considering the increased PDE4 activity, the expression of
PDE4 subtypes has been explored. Although PDE4A mRNA was
not significantly modified (Fig. 3B), Western blot revealed a
specific 44%-increase in a 69 kDa-PDE4A variant (Fig. 4A)
among the three variants expressed (97 kDa, 69 kDa and 58 kDa).
No significant changes for PDE4B and PDE4C mRNA (Fig. 3B)
and protein (not illustrated) expressions were observed. Opposite-
ly, angiotensin II treatment induced significant decreases in
PDE4D variant expressions (219% for 76 kDa and 226% for
52 kDa, Fig. 4B) and PDE4D transcript (254%, Fig. 3B).
PDE3A and PDE3B mRNA expressions were not significantly
changed (Fig. 3).
Effect of angiotensin II treatment on calmodulin-
dependent activation of PDE1
The main characteristic of PDE1 is to be activated by
intracellular calcium concentration increases through association
with Ca
2+/calmodulin (CaM) complexes. To explore the increase
in cGMP-PDE1 activity reported in Figure 2B, we compared
basal PDE1 activity (assessed in presence of EGTA) and CaM-
activated PDE1 (assessed in presence of Ca
2+ and CaM). As seen
above, basal cGMP-PDE1 activity was significantly increased by
134% in ANGII 0.4 rats. But this increase was no longer
significant when PDE1 was activated, by Ca
2+/CaM complexes,
indicating a loss in CaM-dependent activation (Fig. 5A). The ratio
between activated and basal cGMP-PDE1 activities was signifi-
cantly decreased by 29% (Fig. 5C), suggesting that PDE1
activation capacity was more important in control rats that in
ANGII 0.4 rats. PDE1C hydrolyzing both cAMP and cGMP, the
same approach was done for cAMP-PDE1 activity (Fig. 5B). No
significant change in the CaM-dependent activation was observed
between control and ANGII 0.4 rats (Fig. 5C), suggesting that
different PDE1 families contribute to PDE1 activity.
Besides, angiotensin II treatment induced strong increases of
PDE1 expressions. PDE1A mRNA was increased by 140%
(Fig. 3B), associated with a 30% increase of 110 kDa-PDE1A
Early Cardiac Hypertrophy PDEs
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Sequence Product size (pb) GenBank accession no.
PDE1A Forward 59-ACCATGATTGGGTTCCATGTT-39 175 NM_030871
Reverse 59-CAGCCAACTCTTTCCACCT-39
PDE1B Forward 59-TCCACATCCAGACCAAGTCA-39 194 NM_022710
Reverse 59-GCAGGACATGTCTGTGGCT-39
PDE1C Forward 59-CAGCCTACCGTCTTCTCCA-39 179 NM_031078
Reverse 59-TTCAATTGCTTCTGGTTGCTG-39
PDE2A Forward 59-AGTGCTGGGAGAAGAGGTC-39 181 NM_031079
Reverse 59-GTCAGTGGCTCGACTGATG-39
PDE3A Forward 59-GCCCCAGTGTTGATGACTCT-39 161 NM_017337
Reverse 59-GGTGATCCTTGAGGAGGTGA-39
PDE3B Forward 59-ATGGAATTCAAGCGTTTTCG-39 169 NM_017229
Reverse 59-TGCACACCTGGCAGACTAAG-39
PDE4A Forward 59-GAAGACAACCGGGACTGGT-39 172 NM_013101
Reverse 59-CCTCAGTGGTAGGCAATCC-39
PDE4B Forward 59-CCTCCGACACCTTCGTAAC-39 153 NM_017031
Reverse 59-CCAGGTCTGTGAAGACAGC-39
PDE4C Forward 59-GAAGGGCACTACCACTCCA-39 153 XM_001070301
Reverse 59-GTGTATAGCGCACGCAAAGA-39
PDE4D Forward 59-TGGGCAGACCTCGTACATC-39 190 NM_017032
Reverse 59-CAGTGTCTGACTCGCCATC-39
PDE5A Forward 59-GGGAAGAGGTCGTTGGTGT-39 162 NM_133584
Reverse 59-TTTGTTCTCCAGCAGTGACG-39
NOX1 Forward 59-CATGGATGGATCTCTTGCCT-39 168 NM_053683
Reverse 59-ACCATGAGAACCAAAGCCAC-39
NOX2 Forward 59-AACGTGGAGTGGTGTGTGAA-39 222 AF298656
Reverse 59-TTTGGTGGAGGATGTGATGA-39
NOX3 Forward 59-AGTGAACAAGGGAAGGCTCA-39 176 AY573239
Reverse 59-GCAATCTGCTTGAATTCCTCA-39
NOX4 Forward 59-TGTCTGCATGGTGGTGGTAT-39 154 NM_053524
Reverse 59-ATACTTCAACAAGCCACCCG-39
p47phox Forward 59-AGCTCCCAGGTGGTATGATG-39 205 AY029167
Reverse 59-ATCTTTGGCCGTCAGGTATG-39
NOS1 Forward 59-CTGCAAAGCCCTAAGTCCAG-39 207 NM_052799
Reverse 59-AGTGTTCCTCTCCTCCAGCA-39
NOS2 Forward 59-AGGGAGTGTTGTTCCAGGTG-39 232 NM_012611
Reverse 59-TCCTCAACCTGCTCCTCACT-39
NOS3 Forward 59-TGTGACCCTCACCGATACAA-39 212 NM_021838
Reverse 59-CTGGCCTTCTGCTCATTTTC-39
ANP Forward 59-AGCGAGCAGACCGATGAA-39 161 M27498
Reverse 59-GCCCTCAGTTTGCTTTTCAA-39
BNP Forward 59-CAGCTCTCAAAGGACCAAGG-39 191 M25297
Reverse 59-TAAAACAACCTCAGCCCGTC-39
CNP Forward 59-GGCAATCAGAAAAAGGGTGA-39 185 D90219
Reverse 59-CCTTTGGACAAGCCCTTCTT-39
18S rRNA Forward 59-AAACGGCTACCACATCCAAG-39 155 M11188
Reverse 59-CCTCCAATGGATCCTCGTTA-39
doi:10.1371/journal.pone.0014227.t001
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by 54% (Fig. 3B), was associated with an increased expression of
the two detected variants (+41% for the 67 kDa signal and +32%
for the 73 kDa signal) (Fig. 5E). PDE1B mRNA was detected by
real-time PCR without being affected by angiotensin treatment
(Fig. 3B) but PDE1B protein was not detected by Western blot.
Effect of angiotensin II treatment on PDE5
PDE5 was subjected to the most important changes in
expression after angiotensin II treatment. PDE5A mRNA
increased by 121% (Fig. 3B) and was associated with an increase
of the two detected PDE5 variants: + 95% for 97 kDa-signal and
+40% for 83 kDa-signal (Fig. 6D). Furthermore, Ser92-phopho-
sphorylated 97 kDa-PDE5A/PDE5A 97 kDa-protein ratio was
reduced by 43%, indicating a decrease in PDE5A activation by
PKG (Fig. 6E). We also looked at the intracellular localization of
PDE5A. Previous work reported that PDE5A was localized to Z-
bands and that this localization was lost in advanced cardiac
hypertrophy [36]. In our model of early cardiac hypertrophy,
PDE5A localization to Z-bands (Fig. 6B) was not affected by
angiotensin II treatment (Fig. 6C).
PDE2 and natriuretic peptides
cGMP is produced in part by natriuretic peptide receptors.
Natriuretic peptides (ANP, BNP and CNP) are synthesized in the
heart and can exert their effect through an autocrine/paracrine
pathway. Moreover, natriuretic peptide production in heart is
increased in cardiac hypertrophy [7]. We therefore studied the
expression of the natriuretic peptide transcripts in early cardiac
hypertrophy induced by angiotensin II. While ANP and CNP
transcripts were not significantly modified (not illustrated), BNP
transcript was significantly increased by 254% (Fig. 7D).
On the other hand, despite an important increase in cGMP-
PDE2 hydrolysis activity (Fig. 2B), angiotensin II treatment did
not induce any change either in PDE2A mRNA expression
(Fig. 3B) or in PDE2A protein expression (Fig. 7A).
Effect on AMPK
59AMP kinase (AMPK) plays a very important role in heart
energy metabolism and protein synthesis. It produces ATP from
AMP and is activated when the AMP/ATP ratio increases, i.e.
under conditions of stress [37]. As we observed an increased
cAMP hydrolysis into 59AMP, we looked for AMPK activation.
Consistently, an increase of 64% of the Thr172-phosphorylated
AMPKa catalytic subunit was observed (Fig. 8A).
Effect on nitric oxide synthase (NOS) expression
Another source of cGMP is that produced by soluble guanylyl
cyclases in response to NO. Therefore, NOS1, NOS2 and NOS3
expressions were examined in left cardiac ventricle. Early cardiac
Figure 1. Effects of angiotensin II treatment on rat physiological parameters. Systolic blood pressure (A), heart rate (B) and heart/body
weight ratio (C). Rats were treated with angiotensin II at 0.1 mg.kg
21.d
21 (ANGII 0.1; n=8) or 0.4 mg.kg
21.d
21 (ANGII 0.4; n=13). Effects were
expressed in comparison with control rats (n=6). n.s.: not significant; *: P,0.05; **: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0014227.g001
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or NOS2 mRNA expressions (not illustrated), NOS3 mRNA
expression (Fig. 7C) or NOS3 protein expression (Fig. 7B).
Effect on NADPH oxidases
Reactive oxygen species (ROS) have been shown to be
implicated in the development of cardiac hypertrophy [38].
Angiotensin II modulates ROS production through NADPH
oxidase (NOX) activity and expression in heart [39]. We studied
therefore the effect of angiotensin II-induced early cardiac
hypertrophy on the three major NOX enzymes present in the
heart, NOX1, NOX2 (or gp91-phox) and NOX4 [40]. We found
a significant 66% decrease in the mRNA expression of NOX2
(Fig. 8D), while NOX1 and NOX4 mRNA expressions were
unchanged (not illustrated). Activation of NOX2 is known to need
different subunits, and notably p47-phox subunit [38], but we
found no change either in mRNA expression (Fig. 8C)o ri n
protein expression (Fig. 8B) of p47-phox.
Discussion
cAMP- and cGMP-PDE activities, previously determined in our
laboratory on isolated cardiac myocytes from left cardiac ventricle
of adult rats, showed that cAMP hydrolysis activity was almost 3
times greater than that of cGMP and that PDE2 and PDE4 were
the major enzymes implicated [41]. The present results in left
cardiac ventricles of control rats are consistent with those data,
and they highlight the importance of cardiac cAMP catabolism in
regulating cardiac contractility. PDE4 is associated with many
intracellular complexes involved in b-adrenergic signaling, calcium
signaling with the ryanodine receptors and L-type calcium
channels (LTCCs), contraction associated to myofilaments [42]
and lastly IKs potassium channel [43]. PDE2 is also associated with
b-adrenergic signaling complexes and LTCCs. Although the
activity of PDE2 toward the hydrolysis of cAMP is relatively low,
its presence in plasma membrane contributes to regulate the
cardiac LTCC activity when the level of cGMP is increased [44],
since PDE2 inhibits the activation of LTCCs by reducing cAMP
concentration after being activated by cGMP. By this mechanism,
PDE2 establishes a link in the heart between cGMP generated by
guanylyl cyclases and b-adrenergic cAMP signal [45].
Only rats undergoing a two week-treatment with angiotensin II
at 0.4 mg.kg
21.d
21 developed hypertension associated with
cardiac hypertrophy. However, this cardiac hypertrophy was
weak (+24%) indicating that cardiac hypertrophy is in its early
stage.
Figure 2. Effects of angiotensin II treatment on left cardiac ventricle PDE specific activities. cAMP-PDE specific activities and contribution
of PDE2, PDE3 and PDE4 (A). cGMP-PDE specific activities and contributions of PDE1, PDE2, PDE3 and PDE5 (B). cAMP-PDE over cGMP-PDE total
activity ratio (C). Specific activities were determined on total homogenate and expressed as pmol.min
21.mg
21 of protein. Effects on treated rats (&;
n=4) were compared with control rats (%; n=6). n.s.: not significant; *: P,0.05; **: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0014227.g002
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of opposite changes. Indeed, while all detected isoforms of the
PDE4D subfamily were down-regulated, we observed a specific
increase in a short 69 kDa-PDE4A isoform by angiotensin II
treatment, without increase in PDE4A mRNA. This apparent
discrepancy is due to the fact that the set of primers used were
designed to detect all PDE4A mRNAs while three variants were
separated by Western blot. PDE4A seems to be the major
subfamily responsible for cAMP hydrolysis in rat left cardiac
ventricle. It has been shown in isolated rat ventricular myocytes
that PDE4A contribution was one third of total PDE4 activity,
while PDE4D accounted only for 15% [46]. This explains in part
why, despite a decreased PDE4D expression, global cAMP-PDE4
activity is increased. Little is known about the distribution and
role of PDE4A in heart. It was shown that PDE4A1 could be
associated to the Golgi membrane [47]. On the other hand,
PDE4D has already been linked to cardiac diseases and its role in
heart was intensively investigated. Several epidemiologic studies
found an association between PDE4D gene and ischemic stroke
[48,49]. PDE4D deficiency in the ryanodine-receptor complex
(RyR2) in mice was also involved in heart failure. Accumulation
of cAMP contributes to PKA-hyperphosphorylated RyR2
channels leaking calcium that promotes cardiac dysfunction and
arrhythmias [14]. PDE4D3, which is the isoform supposed to be
in the ryanodine-receptor complex, is also associated to
sarcoplasmic [50] and perinuclear [51] membranes. Further-
more, PDE4D was shown to be associated to isolated cardiac
nuclei [52]. Moreover, PDE4D5 is implicated in b2-adrenergic
receptors signaling through b-arrestin interactions [53]. Our data
are consistent with those results and show moreover that this
Figure 3. PDE mRNA distribution in control left cardiac ventricle and effect of angiotensin II treatment. Relative mRNA levels in control
left cardiac ventricle (A). Results were expressed as DCt = Ct of PDE – Ct of 18S rRNA, which corresponds to the number of amplification cycles
needed to detect fluorescence signal, each cycle corresponding to a 2-fold amplification. DCt being inversely proportional to initial PDE mRNA level,
the fewer is DCt, the greater is initial mRNA level. Effects of angiotensin II treatment on PDE mRNA expressions (B). Results were normalized with the
18S rRNA housekeeping gene and expressed as amplification folds relative to control. n.s.: not significant; *: P,0.05; **: P,0.01.
doi:10.1371/journal.pone.0014227.g003
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of cardiac hypertrophy.
The highest cGMP-PDE effect of angiotensin II treatment at
0.4 mg.kg
21.d
21 was on PDE1 activity in its basal state, with a
130% increase. The expressions of 110 kDa-PDE1A, and 67 kDa-
and 73 kDa-PDE1C proteins were similarly increased by angioten-
sin II treatment. But in the same time, PDE1 activation by Ca
2+/
CaM complexes was less important than in control rats. This could
be the result of a PKA-dependent phosphorylation. Indeed, PKA-
dependent phosphorylationof PDE1A and PDE1C has beenshown
to reduce their ability to get activated by Ca
2+/CaM complexes
[54]. However, considering cAMP hydrolysis activity of PDE1
which concerned PDE1C (Fig. 5C), no difference in PDE1 ratio
was observed, suggesting that during cardiac hypertrophy, PDE1A
was specifically PKA-phosphorylated. An increase in PDE1 activity
and PDE1A expression has been reported to be associated with
cardiac hypertrophy induced by abdominal aortic banding in
Sprague-Dawley rats [12], and more recently by neurohumoral
stimuli suchasangiotensin II and isoproterenol[55].Interestingly,it
was shown in cultured rat aortic vascular smooth muscle cells that
angiotensin II treatment upregulates PDE1A [56], suggesting that
such mechanism could participate to PDE1A upregulation
described herein. PDE1A hydrolyzes mainly cGMP and PDE1C
hydrolyzes cGMP and cAMP equally. PDE1C is expressed in rat
heart[57] and PDE1C1isexpressedat high levels inhumancardiac
myocytes [58]. PDE1C has been associated with arterial smooth
muscle cell proliferation in several studies [59,60]. Interestingly, an
increase in PDE1 activity and PDE1C protein was proposed to
explain in part the cardioprotective effect of prostacyclinin ratheart
[57]. Thus, to our knowledge, it is the first time that, additively to
PDE1A,PDE1Cisshowntobeassociatedwithcardiachypertrophy
in the heart.
Angiotensin II treatment induced a 113% increase in PDE5
activity, corresponding to strong increases in both 83 kDa- and
97 kDa-PDE5A isoforms and a 121% increase in PDE5A-mRNA.
This is in agreement with the reported increase of PDE5A
expression induced by angiotensin II in vascular smooth muscle
cells representing a new mechanism by which angiotensin II
antagonizes cGMP signaling [61]. In that way, PDE5 activity and
expression have been reported to be elevated in right ventricular
hypertrophy in rats as well as in humans [21], and cardiac
hypertrophy induced by aortic banding in C57Bl/6 mice [22]. On
one hand, cardiac over-expression of PDE5A in mice predisposed
to left ventricle remodeling [15], and interestingly PDE5A
inactivation by gene silencing blunted phenylephrine-induced
hypertrophy [62]. On the other hand, PDE5 inhibition improved
cardiac contractility [21,63], and prevented and reversed cardiac
hypertrophy [22]. This effect is mediated by one member of the
Regulator of G-protein Signaling family RGS2 [64]. All these
results brought increasing interest in using PDE5 inhibitors in the
treatment of heart failure [65]. Recently, it was shown in the heart
that: i) PDE5A is coupled to NOS3; ii) this coupling targets
PDE5A to a specific intracellular location (Z-bands) enabling
PDE5A to regulate cGMP generated through NOS3 activation in
response to b-adrenergic stimulation; and iii) chronic inhibition of
NOS3 abolishes this localization [36]. Herein, we show that
NOS3 expression is not affected in early cardiac hypertrophy
induced by angiotensin II and that PDE5A keeps a Z-band
localization pattern. Taken together, our data additively show that
PDE5A alterations begin at a very early stage in cardiac
hypertrophy leading to heart failure, and that the reported
increase in PDE5 activity occurs before the loss of its intracellular
localization to Z-bands and alteration of NOS3 expression.
In agreement with PKG activity suppression reported in
hypertrophied human right ventricle [21], a reduction in PDE5A
Ser92 phosphorylation was observed herein indicating a decrease in
PKG activity, which might result from increased cGMP-PDE1,
-PDE2, and -PDE5 activities. Indeed, it was proposed that PDE5
Figure 4. Effect of angiotensin II treatment on cAMP hydrolysis activity. Effects of angiotensin II treatment at 0.4 mg.kg
21.d
21, on protein
expression of PDE4A (A), PDE4D (B). Effects on treated rats (T, &; n=4) were compared with control rats (C, %; n=4). Results were normalized with
GAPDH signal and expressed in percentage of untreated rat. n.s.: not significant; *: P,0.05.
doi:10.1371/journal.pone.0014227.g004
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activation [66]. Furthermore, PDE5A up-regulation might decrease
the cGMP binding to PDE5A GAF domain and consequently its
phosphorylation [67]. These data support a decrease in the
availability ofcGMP inthe vicinityof PDE5,most likely to Z-bands.
PDE regulation is complex and one transduction signal may
affect several PDEs. For example, cAMP differentially regulates
PDEs through PKA by activating PDE4 and decreasing PDE1
activation [68]. Regarding cGMP, we could think that PDE1 and
PDE5 may have a common pattern of regulation in cardiomyo-
cytes. Indeed, they share some common intracellular localization
like the Z-bands [36,58,69] and participate to contractile events
[70,71]. They are implicated also in cell growth and survival with
nuclear localizations for PDE1A [71] and PDE1C [69] and
centrosomal localization for PDE5A [69]. Their activities were
simultaneously increased in vascular smooth muscle cell prolifer-
ation [60,70] and herein in cardiac hypertrophy. Their increases
might participate together to nitrate tolerance, since combination
of nitrates with PDE5 inhibitors [72] or PDE1 inhibitors [73]
improved pulmonary vasodilator response in pulmonary arterial
hypertension. It was also suggested that sildenafil improved
vasodilatation in pulmonary hypertension through PDE5 and
PDE1 inhibitions [74]. Very few data are available in cardiac
myocytes due to lack of simultaneous studies on PDE1 and PDE5.
Angiotensin II treatment at 0.4 mg.kg
21.d
21 induced a 76%
increase in cGMP-PDE2 activity in cardiac ventricles without any
change in expression. This suggests that increased PDE2 activity
was the result of a post-translational regulation. Such increased
PDE2 activity, without increased expression, has previously been
reported in another rat cardiac hypertrophy model induced by
abdominal aortic banding [12]. It was shown that PDE2 could be
activated by protein kinase C (PKC)-dependent phosphorylation
[75]. Since PKC is part of the AT1 receptor signaling pathway
and is likely to be activated after angiotensin II stimulation, the
increase in PDE2 activity subsequent to angiotensin treatment
might be PKC-mediated [5]. In rat ventricular cardiomyocytes,
stimulation of soluble or particulate GC to the production of
cGMP in different functional compartments, which access is
restricted to different cGMP-PDEs. For example, cGMP produced
by particulate GC would be exclusively under the control of
PDE2, whereas that produced by soluble GC would be under the
control of PDE2 and PDE5 [76]. We observed an up-regulation of
the brain natriuretic peptide which stimulates its receptor, through
an autocrine/paracrine action, increasing the ‘‘particulate’’ cGMP
pool [7]. It was reported that natriuretic peptides could inhibit
angiotensin II-induced proliferation of rat cardiac fibroblasts
through cGMP-dependent mechanism [77]. The increased PDE2
activity observed might then oppose the BNP-induced cGMP
Figure 5. Effect of angiotensin II treatment on PDE1 activity in left cardiac ventricle. cGMP-PDE1 specific activity (A), cAMP-PDE1 specific
activity (B), and PDE1 activated over basal activity ratio (C). Basal PDE1 activity was assessed in presence of EGTA and CaM-activated PDE1 was
assessed in presence of Ca
2+ and CaM. Effects on treated rats (T, &; n=4) were compared with control rats (C, %; n=6). Specific activities were
determined on total homogenate and expressed as pmol.min
21.mg
21 of protein. Effects of angiotensin II treatment on protein expression of PDE1A
(D) and PDE1C (E). Results were normalized with GAPDH signal and expressed in percentage of untreated rat. n.s.: not significant; *: P,0.05;
**: P,0.01; ***: P,0.001.
doi:10.1371/journal.pone.0014227.g005
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was shown that natriuretic peptide desensitization in heart failure
relates, in part, to increased PDE5 activity, supporting a
therapeutic role for PDE5 inhibition [78]. Furthermore, stimula-
tion of isolated cardiomyocytes by phenylephrine induced
hypertrophy, and PDE5A over-expression amplified natriuretic
peptide gene expression from phenylephrine stimulation [62]. It is
the first time that such PDE2 activation is reported in angiotensin
II induced hypertrophy, strengthening previous data in aortic
banding-induced cardiac hypertrophy in Sprague-Dawley rats
[12].
As a direct consequence of increased PDE4 activity which,
degrades cAMP, the increase of 59AMP could lead to AMPK
activation through an increase in AMP/ATP ratio. This
hypothesis is supported by a recent work showing that IL-6
activates AMPK in skeletal muscle by transiently increasing the
concentration of cAMP and, secondarily, the AMP/ATP ratio
[79]. AMPK is a heterotrimeric protein consisting of a catalytic a
subunit and b and c regulatory subunits and is a serine/threonine
protein kinase [80]. It is a key metabolic regulator that is
activated under stress conditions. Its exact role in cardiac diseases
is until now not well defined, but in recent studies an overall
cardioprotective role of AMPK was suggested [37,81]. Indeed,
AMPK activation with AICAR (5-amino-4-imidazolecarboxa-
mide riboside, an AMPK activator) inhibited growth and
proliferation in rat neonatal cardiac fibroblasts [82]. AMPKa2
deficiency was shown to enhance myocardial ischemia/reperfu-
sion injury in a mouse model with cardiomyocyte-specific
overexpression of a mutant AMPKa2 catalytic subunit [83],
and to exacerbate pressure overload induced left ventricular
Figure 6. Effects of angiotensin II treatment on PDE5 expression and intracellular localization. Immunostaining of PDE5A cellular
distribution in left cardiac ventricle: negative control (A), control rats (B) and angiotensin II treated rats (C). PDE5A is localized to Z-bands. Effects of
angiotensin II treatment at 0.4 mg.kg
21.d
21 on protein expression of PDE5A (D) and phospho-PDE5A over 97 kDa PDE5A (E). Effects on treated rats
(T, &; n=4) were compared with control rats (C, %; n=4). Results were normalized with GAPDH signal and expressed in percentage of untreated rat.
*: P,0.05.
doi:10.1371/journal.pone.0014227.g006
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Direct and indirect activation of AMPK was also shown to have
cardioprotective properties. Metformin was able to induce
AMPK phosphorylation and to improve left ventricular function
and survival in heart failure [85]. Resveratrol was also shown to
inhibit cardiac hypertrophy in part through AMPK activation
[86]. In rat neonatal cardiomyocytes, angiotensin II-induced
hypertrophy was accompanied by a decreased activation of
AMPK, and stimulation with the AMPK-activator AICAR
inhibited this hypertrophy [87]. Long-term activation of AMPK
with AICAR was also shown to attenuate cardiac hypertrophy
induced by pressure overload [88]. Moreover, a recent study
showed that the anesthetic sevoflurane induced AMPK activation
protects the heart against ischemia and reperfusion injury, and
relies on upstream production of ROS [89]. In our cardiac
hypertrophy model, AMPK phosphorylation was increased by
64%. This activation might be the result of increased generation
of 59AMP by PDE4 activity, and therefore might be a
physiological mechanism to oppose left ventricular hypertrophy
induced by angiotensin II.
The implication of NOX and ROS in cardiac remodeling has
been well documented (for review see [90,91]). For example, it was
shown in rat neonatal cardiomyocytes that NOX2 [92] is
implicated in the cardiac hypertrophic effect of angiotensin II.
Surprisingly, we observed a 66% decrease in the NOX2 mRNA
expression. However, it was recently shown that natriuretic
peptides such as ANP have antihypertrophic effect on cardiomy-
ocytes, in part by counteracting increased ROS generation and
NOX2 expression induced by angiotensin II [93]. Moreover, a
recent study showed that AMPKa2 subunit functions as a
physiological suppressor of NAD(P)H oxidase (NOX) and ROS
production in endothelial cells [94]. It was also suggested that
AMPK may enhance NO bioavailability indirectly through
antioxidative mechanisms by limiting superoxide-triggered NO
consumption and consecutive peroxynitrite (ONOO
-) production,
e.g., by inhibiting NOX [95,96]. We could then make the
Figure 7. Effects of angiotensin II treatment on PDE2, BNP and NOS. Expression of PDE2A protein (A), NOS3 protein (B), NOS3 mRNA (C) and
BNP mRNA (D). Effects on treated rats (T, &; n=4) were compared with control rats (C, %; n=4). Western blot results were normalized with GAPDH
signal and expressed in percentage of untreated rat. Q-RT-PCR results were normalized with the 18S rRNA housekeeping gene and expressed as
amplification folds relative to control. n.s.: not significant; *: P,0.05.
doi:10.1371/journal.pone.0014227.g007
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have a negative effect on NOX2 expression, at least in the early
stages of cardiac hypertrophy development.
Cardiac hypertrophy and its progression to heart failure
represent a major risk of sudden death. We show in this work
that the early stages of cardiac hypertrophy induced by
angiotensin II are associated with deep alterations in cAMP- and
cGMP-PDE activities. While a specific rise in cAMP-PDE4
activity is observed, cGMP-PDEs activities (PDE1, PDE2 and
PDE5) are broadly increased favoring a greater cGMP hydrolysis.
This result is of particular interest knowing that previous works on
other models focused either on cAMP- or cGMP-PDEs. PDE4D is
strongly down-regulated, while PDE1A and PDE5A are highly up-
regulated. Each of these alterations has already been reported in
advanced cardiac hypertrophy and heart failure. Herein we show
that these changes occur and vary in an opposing manner from the
very beginning of the development of cardiac hypertrophy,
confirming their potential role as targets in cardiac hypertrophy
prevention. Moreover, we highlight for the first time that PDE1C
is present in left cardiac ventricle and increased in early stages of
cardiac hypertrophy. The role of PDE1 family in the heart has
only very recently raised interest and is still not well known.
Furthermore, we report that PDE2 accounts for the main
contribution in cGMP-PDE activity in rat left cardiac ventricle
and that PDE2 activity increases in the early stages of cardiac
hypertrophy through a post-translational regulation. Finally,
associated with the global increased cGMP hydrolysis in
hypertrophic left cardiac ventricle, we observe the establishment
at the PDE levels of two cardioprotective mechanisms and we
suggest that these mechanisms could lead to increase cGMP: i)
expression of natriuretic peptides could increase ‘‘particulate’’
cGMP pool; ii) activation of AMPK, subsequent to increase in
PDE4 activity, could increase ‘‘soluble’’ cGMP pool through
enhanced NO bioavailability (Fig. 9). More studies are needed to
support these assumptions. Nevertheless, our results suggest a
potential link between PDE4 and AMPK/NOX2 and that cGMP-
Figure 8. Effects of angiotensin II treatment on AMPK and NADPH oxidase. Expressions of the phosphorylated a-catalytic subunit of AMPK
(A), p47-phox protein (B), p47-phox mRNA (C) and NOX2 mRNA (D). Effects on treated rats (T, &; n=4) were compared with control rats (C, %; n=4).
Western blot results are expressed in percentage after correcting PDE signal with GAPDH signal. Q-RT-PCR results were normalized with the 18S rRNA
housekeeping gene and expressed as amplification folds relative to control. n.s.: not significant; *: P,0.05.
doi:10.1371/journal.pone.0014227.g008
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targets in preventing cardiac hypertrophy.
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